Compare Pfizer Inc (PFE) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Trade Desk Inc — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while Trade Desk Inc trades at $12.29 (market cap $5.83B). The key difference: Pfizer Inc is far larger — about 27.2× Trade Desk Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Trade Desk Inc for 72 Days on average.
| PFE | TTD | |
|---|---|---|
Market Cap | $158.56B | $5.83B |
Volume | 44,138,282 | 15,864,392 |
Sector | Health | Media |
52-Week High | $29.02 | $54.13 |
52-Week Low | $23.67 | $11.92 |
Typical Hold Time | 158 Days | 72 Days |
Enterprise Value | $210.06B | $4.78B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
The Trade Desk (TTD) trades at $12.09, down 67% year-to-date amid slowing revenue growth and increased competition. The stock shows bearish technical signals with mixed earnings performance - beating Q4 2025 and Q2 2026 estimates but missing Q1 2026. Despite strong profitability metrics including 76.87% gross margins and 15.44% ROE, the company faces headwinds from Amazon and other tech giants entering the ad-tech space, with recent workforce reductions signaling operational challenges.
While TTD maintains leadership in programmatic advertising with healthy cash flow generation, near-term outlook remains cautious due to competitive pressures and slowing growth. The stock trades at attractive valuation multiples (P/E 0.15, P/S 0.02) but requires clear catalysts to reverse the downward trend. Investors should weigh the company's strong market position against execution risks in a rapidly evolving digital advertising landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
